Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Continuous Glucose Monitoring: Expert Answers to FAQs

Common questions from the Diabetes Medical Minutes Series on continuous glucose monitoring.
Vivian A. Fonseca, MD, FRCP
Program Director
Kushner_Pamela_32x32
Pamela Kushner, MD, FAAFP
Format: Adobe Acrobat (.pdf)
File Size: 194 KB
Released: April 22, 2020

Acknowledgements

Provided by Endocrine Society

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by an educational grant from
Lilly

Related Content

From Dr. Carol Hatch Wysham and Clinical Care Options (CCO), expert commentary on improving care for type 2 diabetes

Carol Hatch Wysham, MD Released: October 7, 2021

Short video from Clinical Care Options (CCO) featuring expert insights on the clinical management of persons with T2D and metabolic comorbidities

Carol Hatch Wysham, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Registered Dieticians/Dietetic Technicians, Registered: maximum of 0.5 CPEU(s) Released: September 30, 2021 Expired: September 29, 2022

From Dr. Carol Hatch Wysham and Clinical Care Options (CCO), expert commentary on emerging data on tirzepatide for type 2 diabetes

Carol Hatch Wysham, MD Released: September 21, 2021

Downloadable slides from Clinical Care Options (CCO) featuring expert insights on the clinical trial data supporting the use of tirzepatide in T2D

Carol Hatch Wysham, MD Released: September 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue